CD104 (Integrin β4), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG

Search, find, compare suppliers for anti-CD104 (Integrin β4), Human antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityCD104 (Integrin β4), Human
CloneREA236
Host SpeciesRecombinant Human
Reactive Specieshuman
IsotypeIgG1
FormatAPC-Vio 770 conjugate
Size100 tests in 1 mL
Concentration1:11
ApplicationsFlow cytometry
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionCD104 (Integrin β4) Antibody, anti-human, APC-Vio® 770, REAfinity™. Clone REA236 recognizes CD104, which is also known as integrin β4. Integrins are a family of type I transmembrane heterodimeric glycoprotein receptors and exist as non-covalently bound α and β subunits. CD104 interacts with α6 integrin and serves as receptor for laminin and component of hemidesmosomes. Expression of α6β4 integrin is found in the basal aspect of stratified epithelia such as epidermis, stratified squamous epithelium of squamous mucosa, urothelium, and certain tumor cells. | Additional information: Clone REA236 displays negligible binding to Fc receptors. |
Immunogenn/a
Other NamesItgb4
Gene, Accession #Gene ID: 3691
Catalog #130-101-424
Price$360
Order / More InfoCD104 (Integrin β4), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Product Specific ReferencesSimon-Assmann, P. et al. (1994) Differential expression of laminin isoforms and alpha 6-beta 4 integrin subunits in the developing human and mouse intestine. Dev. Dyn. 201 (1): 71-85. | Tuckwell, D. S. et al. (1993) Integrins: a review of their structure and mechanisms of ligand binding. Symp. Soc. Exp. Biol 47: 107-136.
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197

macs@miltenyibiotec.de

https://www.miltenyibiotec.com

Profile of MILTENYI BIOTEC B.V. & Co. KG

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.